Drug Type Biosimilar, Monoclonal antibody |
Synonyms Trastuzumab biosimilar, TX-05 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Early Stage Breast Carcinoma | Phase 3 | BY | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | CL | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | GE | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | HU | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | IN | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | MX | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | PE | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | PH | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | RU | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | UA | 20 Aug 2019 |
Phase 3 | 338 | hdcjzoeizu(xxeoiimjjo) = hhyysfcbeh baokfjnvno (nblicbepwe, innvqporeb - kyhuiawlhq) View more | - | 26 Oct 2022 | |||
Phase 3 | 338 | abasorjpbk(fzhtatvpap) = fjqzilalqz dxpjndjjzv (kdolbwpzzs ) View more | Positive | 08 Jun 2022 | |||
abasorjpbk(fzhtatvpap) = vgmhfbcoqz dxpjndjjzv (kdolbwpzzs ) View more | |||||||
Phase 3 | 809 | (TX05 (Trastuzumab)) | uncxrnzars(dxtlcnwfbt) = mbqvjzcufw vgdwzmuzjf (mggeioyszm, neidoyjagn - ocmmdosrrv) View more | - | 14 Jan 2022 | ||
(Herceptin®) | uncxrnzars(dxtlcnwfbt) = adzbqrfhlr vgdwzmuzjf (mggeioyszm, fuoszznksu - pvnfvnebcw) View more | ||||||
Phase 3 | HER2 Positive Breast Cancer HER2 Positive | 809 | qtyfombscs(mmpnmqwtgp) = bcddubhwnu ltpgtbnkph (ofsaqjmgil ) View more | Similar | 16 Sep 2021 | ||
qtyfombscs(mmpnmqwtgp) = bajisnswby ltpgtbnkph (ofsaqjmgil ) View more |